About
DermR Health is transforming skin cancer diagnostics with the DermR Patch, a world-first, non-invasive microneedle patch that painlessly collects live skin cells for genomic testing. This groundbreaking solution addresses the global challenge of inefficient skin cancer diagnosis, where 40% of biopsies are benign and avoidable. DermR’s technology is designed for doctors, nurses, and allied health professionals, integrating seamlessly into existing pathology workflows to provide faster, more accurate results. After successful first-in-human clinical trials, DermR is raising $5M AUD to fund the final two clinical trials for regulatory approval, positioning the company for acquisition by pathology networks or MedTech firms.